Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87


Prediction and identification of potential immunodominant epitopes in glycoproteins B, C, E, G, and I of herpes simplex virus type 2.

Pan M, Wang X, Liao J, Yin D, Li S, Pan Y, Wang Y, Xie G, Zhang S, Li Y.

Clin Dev Immunol. 2012;2012:205313. doi: 10.1155/2012/205313. Epub 2012 May 9.


Design and evaluation of a multi-epitope assembly peptide (MEAP) against herpes simplex virus type 2 infection in BALB/c mice.

Wang X, Xie G, Liao J, Yin D, Guan W, Pan M, Li J, Li Y.

Virol J. 2011 May 16;8:232. doi: 10.1186/1743-422X-8-232.


Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes.

Awasthi S, Huang J, Shaw C, Friedman HM.

J Virol. 2014 Aug;88(15):8421-32. doi: 10.1128/JVI.01130-14. Epub 2014 May 14.


Identification of type-specific domains within glycoprotein G of herpes simplex virus type 2 (HSV-2) recognized by the majority of patients infected with HSV-2, but not by those infected with HSV-1.

Grabowska A, Jameson C, Laing P, Jeansson S, Sjögren-Jansson E, Taylor J, Cunningham A, Irving WL.

J Gen Virol. 1999 Jul;80 ( Pt 7):1789-98.


Better neutralization of herpes simplex virus type 1 (HSV-1) than HSV-2 by antibody from recipients of GlaxoSmithKline HSV-2 glycoprotein D2 subunit vaccine.

Awasthi S, Belshe RB, Friedman HM.

J Infect Dis. 2014 Aug 15;210(4):571-5. doi: 10.1093/infdis/jiu177. Epub 2014 Mar 20.


Immunodominant epitopes in herpes simplex virus type 2 glycoprotein D are recognized by CD4 lymphocytes from both HSV-1 and HSV-2 seropositive subjects.

Kim M, Taylor J, Sidney J, Mikloska Z, Bodsworth N, Lagios K, Dunckley H, Byth-Wilson K, Denis M, Finlayson R, Khanna R, Sette A, Cunningham AL.

J Immunol. 2008 Nov 1;181(9):6604-15.


Impact of valency of a glycoprotein B-specific monoclonal antibody on neutralization of herpes simplex virus.

Krawczyk A, Krauss J, Eis-Hübinger AM, Däumer MP, Schwarzenbacher R, Dittmer U, Schneweis KE, Jäger D, Roggendorf M, Arndt MA.

J Virol. 2011 Feb;85(4):1793-803. doi: 10.1128/JVI.01924-10. Epub 2010 Dec 1.


Localization of type-specific epitopes of herpes simplex virus type 2 glycoprotein G recognized by human and mouse antibodies.

Liljeqvist JA, Trybala E, Svennerholm B, Jeansson S, Sjögren-Jansson E, Bergström T.

J Gen Virol. 1998 May;79 ( Pt 5):1215-24.


Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread.

Awasthi S, Zumbrun EE, Si H, Wang F, Shaw CE, Cai M, Lubinski JM, Barrett SM, Balliet JW, Flynn JA, Casimiro DR, Bryan JT, Friedman HM.

J Virol. 2012 Apr;86(8):4586-98. doi: 10.1128/JVI.07203-11. Epub 2012 Feb 8.


Identification of B- and T-cell epitopes from glycoprotein B of herpes simplex virus 2 and evaluation of their immunogenicity and protection efficacy.

Liu K, Jiang D, Zhang L, Yao Z, Chen Z, Yu S, Wang X.

Vaccine. 2012 Apr 19;30(19):3034-41. doi: 10.1016/j.vaccine.2011.10.010. Epub 2011 Oct 18.


Immunisation with phage displaying peptides representing single epitopes of the glycoprotein G can give rise to partial protective immunity to HSV-2.

Grabowska AM, Jennings R, Laing P, Darsley M, Jameson CL, Swift L, Irving WL.

Virology. 2000 Mar 30;269(1):47-53.


Identification of a herpes B virus-specific glycoprotein d immunodominant epitope recognized by natural and foreign hosts.

Perelygina L, Zurkuhlen H, Patrusheva I, Hilliard JK.

J Infect Dis. 2002 Aug 15;186(4):453-61. Epub 2002 Aug 2.


Identification of novel immunodominant CD4+ Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity.

BenMohamed L, Bertrand G, McNamara CD, Gras-Masse H, Hammer J, Wechsler SL, Nesburn AB.

J Virol. 2003 Sep;77(17):9463-73.


A branched, synthetic oligopeptide corresponding to a region of glycoprotein G of HSV-1 reacts sensitively and specifically with HSV-1 antibodies in an ELISA.

Kasubi MJ, Nilsen A, Marsden HS, Bergström T, Langeland N, Haarr L.

J Virol Methods. 2005 May;125(2):137-43.


Antibodies against synthetic peptides of herpes simplex virus type 1 glycoprotein D and their capability to neutralize viral infectivity in vitro.

Weijer WJ, Drijfhout JW, Geerligs HJ, Bloemhoff W, Feijlbrief M, Bos CA, Hoogerhout P, Kerling KE, Popken-Boer T, Slopsema K, et al.

J Virol. 1988 Feb;62(2):501-10.


Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group.

Corey L, Langenberg AG, Ashley R, Sekulovich RE, Izu AE, Douglas JM Jr, Handsfield HH, Warren T, Marr L, Tyring S, DiCarlo R, Adimora AA, Leone P, Dekker CL, Burke RL, Leong WP, Straus SE.

JAMA. 1999 Jul 28;282(4):331-40.


Supplemental Content

Support Center